The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Disulfide‐Bridged Organosilica Frameworks: Designed, Synthesis, Redox‐Triggered Biodegradation, and Nanobiomedical Applications
Open accessAbstract
Over the past few years, silica‐based nanotheranostics have demonstrated their great potential for nano/biomedical applications. However, the uncontrollable and difficult degradability of their pure silica framework and long‐time in vivo retention still cause severe and unpredictable toxicity risks. Therefore, it is highly desirable to design and synthesize materials with safer framework structures and compositions. To this aim, the introduction of disulfide bonds into the silica framework can not only maintain high stability in physiological conditions, but also achieve a stimuli‐responsive biodegradation triggered by intracellular reducing microenvironment in living cells, especially in cancer cells. Once nanotheranostics with disulfide (i.e., thioether)‐bridged silsesquioxane framework are taken up by tumor cells via passive or active targeting, the disulfide bonds in the hybrid silica matrix can be cleaved by a high concentration of intracellular glutathione, enabling redox‐triggered biodegradation of the nanosystems for both concomitant release of the loaded therapeutic cargo and in vivo clearance. It is envisioned that such hybrid materials comprised of disulfide‐bridged silsesquioxane frameworks can become promising responsive and biodegradable nanotheranostics. This review summarizes the recent advances in the synthesis of hybrid organosilicas with disulfide‐bridged silsesquioxane frameworks, and discuss their redox‐triggered biodegradation behaviors combined with their biocompatibility and nanobiomedical applications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Principles of nanoparticle design for overcoming biological barriers to drug delivery
Blanco, E., Shen, H., & Ferrari, M. (2015) · Nature Biotechnology · doi:10.1038/nbt.3330 · Cited by 7,002
Renal clearance of quantum dots
Soo Choi, H., Liu, W., Misra, P., Tanaka, E., Zimmer, J. P., Itty Ipe, B., Bawendi, M. G., & Frangioni, J. V. (2007) · Nature Biotechnology · doi:10.1038/nbt1340 · Cited by 4,476
Poly(ethylene glycol) in Drug Delivery: Pros and Cons as Well as Potential Alternatives
Knop, K., Hoogenboom, R., Fischer, D., & Schubert, U. S. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.200902672 · Cited by 3,533
Longmire, M., Choyke, P. L., & Kobayashi, H. (2008) · Nanomedicine · doi:10.2217/17435889.3.5.703 · Cited by 2,149
Kim, S. E., Zhang, L., Ma, K., Riegman, M., Chen, F., Ingold, I., Conrad, M., Turker, M. Z., Gao, M., Jiang, X., et al. (2016) · Nature Nanotechnology · doi:10.1038/nnano.2016.164 · Cited by 622
Emerging understanding of the protein corona at the nano-bio interfaces
Mahmoudi, M., Bertrand, N., Zope, H., & Farokhzad, O. C. (2016) · Nano Today · doi:10.1016/j.nantod.2016.10.005 · Cited by 250
Kim, J. H., Fang, B., Song, M. Y., & Yu, J.-S. (2012) · Chemistry of Materials · doi:10.1021/cm203520a · Cited by 72
Cited by
Mesoporous silica nanoparticles for therapeutic/diagnostic applications
Jafari, S., Derakhshankhah, H., Alaei, L., Fattahi, A., Varnamkhasti, B. S., & Saboury, A. A. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.10.167 · Cited by 566
Stimuli‐Responsive Nanoparticles for Controlled Drug Delivery in Synergistic Cancer Immunotherapy
Zhang, J., Lin, Y., Lin, Z., Wei, Q., Qian, J., Ruan, R., Jiang, X., Hou, L., Song, J., Ding, J., et al. (2022) · Advanced Science · doi:10.1002/advs.202103444 · Cited by 292
Janjua, T. I., Cao, Y., Kleitz, F., Linden, M., Yu, C., & Popat, A. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115115 · Cited by 259
Self-citation
Metadata
- Authors
- Du, X., Kleitz, F., Li, X., Huang, H., Zhang, X., & Qiao, S.
- Venue
- Advanced Functional Materials
- Publisher
- Wiley
- Published
- 2018-04-25
- Volume
- 28
- Issue
- 26
- ISSN
- 1616-301X (ISSN-L)
- 1616-3028
- OpenAlex
- W2800086373
- Cited by
- 196
- References
- 7
- FWCI
- 9.85
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.